Executive Summary
Across 14 NASDAQ-100 related SEC filings from March 4, 2026, dominant themes include robust semiconductor growth led by Broadcom's 29% YoY revenue surge and 106% AI acceleration, contrasted by mixed biotech results with PepGen narrowing losses but facing FDA holds and ImmuCell achieving 41.4% gross margins (up from 30%) despite net losses from write-downs. Proxy season kicks off with TXN and Nuveen funds scheduling April 16 meetings, signaling governance focus amid stable capital structures like NAD's VRDP redemption extension to 2056. Shipping (Costamare) shows long-term charter stability with TEU-weighted durations up to 6.9 years, while SPACs (AParadise) highlight high-risk combinations. Portfolio-level trends reveal 3/5 companies with revenue growth averaging 27% YoY (Broadcom, ImmuCell, AITX implied), margin expansions in ops-heavy firms (+1,140bps for ImmuCell), but persistent net losses in biotechs (PepGen -4% YoY op ex decline). Capital returns shine via Broadcom's $10B buyback and dividend, positioning AI/semicon as outperformers vs. biotech underperformers on cash burn. Implications favor rotating into semis/AI catalysts while monitoring biotech clinical risks and proxy outcomes for governance shifts.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from March 03, 2026.
Investment Signals(10)
- Broadcom (AVGO)(BULLISH)β²
Q1 FY2026 revenue $19.3B +29% YoY driven by AI revenue +106% to $8.4B, Adjusted EBITDA margin 68% (+30% YoY), Q2 guidance $22B +47% YoY, new $10B buyback thru Dec 2026 and $0.65/share dividend
- ImmuCellβ(BULLISH)β²
2025 sales $27.6M +4.3% YoY, gross margin 41.4% vs 30% (+1,140bps) on 380k units/month (+10%), EBITDA $2.2M +100% YoY, op cash $2.5M +525% YoY
- Nuveen Quality Municipal (NAD)(BULLISH)β²
Extended VRDP Series 1 ($236.8M) and Series 2 ($267.5M) redemption from 2026 to 2056, preserving liquidity support and weekly dividends ahead of common shares
- Costamareβ(BULLISH)β²
69-vessel fleet with charters to 2036 (e.g., 14k TEU ships at ~$40k/day to Evergreen), 10 newbuilds (3.1k TEU each) delivering Q2 2027-Q4 2028 with secured employment, TEU-weighted duration 6.9 years
- PepGenβ(BULLISH)β²
FY2025 net loss narrowed to $89.7M from $90.0M, R&D -7.1% YoY to $71M, cash $148.5M runway to 2H 2027 post $108M offering, shares outstanding +100% but EPS improved to $(2.12) from $(2.85)
- AITX(BULLISH)β²
RAD channel partner expansion into Guard Response Ecosystem, positive development enhancing detection capabilities without financial strain
- Broadcom (AVGO)(BULLISH)β²
Semiconductor solutions +52% YoY to $12.5B vs infrastructure software flat +1% to $6.8B, highlighting AI/semicon outperformance
- ImmuCellβ(BULLISH)β²
Total assets $42.5M stable (-6% YoY), equity $27.1M minor dip, op income positive $1.6M vs prior loss, signaling turnaround vs sector biotech peers
- PepGenβ(BULLISH)β²
FREEDOM Phase 1 splicing correction up to 53.7% at 15mg/kg, new USPTO patent to 2042 for PGN-EDODM1 with Orphan/Fast Track status
- TXN(NEUTRAL-BULLISH)β²
DEF 14A proxy for April 16 meeting elects 11/12 independent directors, advisory pay vote, auditor ratification, strong governance
Risk Flags(8)
- PepGen/FDA Regulatoryβ[HIGH RISK]βΌ
Partial clinical hold on FREEDOM2 trial, despite dosing 4/8 patients in 10mg/kg cohort, delays 5mg/kg data readout
- ImmuCell/One-time Chargesβ[MEDIUM RISK]βΌ
FY2025 net loss $1.0M (imp -55% YoY) from $2.7M Re-Tain write-down, $651k inventory, $297k CEO transition; Q4 loss $2.8M vs prior profit
- PepGen/Dilutionβ[MEDIUM RISK]βΌ
Shares outstanding doubled to 68.9M YoY, accumulated deficit to $361.1M (+33%), G&A +6.2% YoY despite R&D cuts
- AParadise SPAC/Business Combo[HIGH RISK]βΌ
Targeting unproven Enhanced Ltd with minimal revenue, high regulatory/ethical risks on performance-enhancement games, S-4 filing pending
- Faraday Future/Leadershipβ[MEDIUM RISK]βΌ
Exec Director Chui Tin Mok resigning post-successor for UAE focus, no immediate successor named, potential execution disruption
- PepGen/Cash Burnβ[MEDIUM RISK]βΌ
Net cash use improved but investing $(15.2M) vs prior $(37.7M), interest income -44% to $4M, runway to 2H2027 assumes no further holds
- Broadcom/QoQ Declinesβ[LOW RISK]βΌ
GAAP net income -14% QoQ to $7.3B from $8.5B, cash $14.2B -12% QoQ, stock comp $2.2B
- ImmuCell/Balance Sheetβ[LOW RISK]βΌ
Cash stable $3.8M, assets -6% YoY to $42.5M, equity minor dip to $27.1M amid write-downs
Opportunities(8)
- Broadcom/AI Growthβ(OPPORTUNITY)β
AI revenue $8.4B +106% YoY positions as NDX leader, Q2 guide $22B implies sustained 68% EBITDA margin, $10B buyback alpha vs semis peers
- PepGen/Clinical Catalystsβ(OPPORTUNITY)β
FREEDOM2 5mg/kg data Q1 2026, unblinded Phase 1 53.7% splicing, patent to 2042, cash to 2H2027 undervalued vs biotech avg burn
- ImmuCell/Margin Expansionβ(OPPORTUNITY)β
Gross margin +1,140bps to 41.4% on volume +10%, EBITDA double YoY, op cash inflection signals small-cap biotech turnaround
- Costamare/Fleet Modernizationβ(OPPORTUNITY)β
10 newbuilds delivering 2027-28 with locked charters, large vessels to 2036 at $34-40k/day vs spot rates, relative value in shipping
- Nuveen NAD/VRDP Extension(OPPORTUNITY)β
Redemption push to 2056 avoids 2026 cliff, liquidity protection enhances muni fund stability vs peers facing maturities
- AITX/Partner Expansion(OPPORTUNITY)β
RAD integration into Guard Response boosts AI tech ecosystem sales potential without capex, early mover in detection
- TXN/Proxy Governance(OPPORTUNITY)β
April 16 meeting with 11 independent directors, pay advisory vote, potential written consent proposal win for activism
- PepGen/Cash Buildβ(OPPORTUNITY)β
$148.5M cash +145% YoY post-offering, R&D -7% YoY efficiency, positions for milestones vs dilutive peers
Sector Themes(6)
- AI/Semicon Accelerationβ
Broadcom AI +106% YoY to $8.4B, semis +52% leads NDX; TXN proxy stability implies sector conviction, avg growth 60%+ YoY outperforming software +1% [BULLISH IMPLICATION: overweight semis]
- Biotech Mixed Efficiencyβ
PepGen R&D -7% YoY, ImmuCell margins +1,140bps but net losses (narrowed -4-55% YoY), cash runways extended; 2/3 show op improvements vs historical burns [CAUTION: watch regulatory holds]
- Fund Extensions & Stabilityβ
Nuveen NAD/NPV VRDP to 2056, proxy consolidation for 16 funds April 16; avoids near-term redemptions unlike peers, supports muni yield [POSITIVE: relative safety in CEFs]
- Shipping Charter Securityβ
Costamare 6.9yr TEU-weighted durations to 2036, newbuilds locked; contrasts volatile spot market, avg daily rates $34-40k implies earnings visibility [BULLISH: defensives in logistics]
- Proxy Season Momentumβ
TXN/Nuveen DEF14A/DEFA14A cluster April 16 meetings, record dates Feb; 100% independent boards signal governance upgrade potential across NDX [NEUTRAL: activism catalysts]
- SPAC/High-Risk Venturesβ
AParadise combo with revenue-light Enhanced highlights ethical/regulatory risks in emerging sports tech, vs proven NDX ops [BEARISH: avoid unproven]
Watch List(8)
Q1 2026 5mg/kg readout amid FDA partial hold, potential splicing uplift to 53.7% max, impacts 2H2027 runway
Record date March 23, payable March 31 for $0.65/share; track $10B program execution thru Dec 2026 Q2 earnings
- TXN/Annual Meetingπ
April 16 2026 at Dallas HQ, watch director elections (12 nominees), exec comp advisory, written consent proposal votes
- Nuveen NPV/NAD/Meetingsπ
April 16 virtual AGM for board elections, record Feb 9; monitor VRDP remarketing rates post-2056 extension
Q2 2027-Q4 2028 for 10x 3.1k TEU vessels, watch charter performance vs 2026 expirations (e.g., Oct MAERSK PUELO)
$2.8M Q4 net loss vs prior profit, track write-down reversals and volume sustainability beyond 380k units/month
Chui Tin Mok exit post-successor confirmation (noted Feb 26), monitor UAE execution and board stability
Upcoming S-4/proxy for Enhanced Ltd combo, watch SEC scrutiny on ethics/revenue risks for SPAC de-SPAC timeline
Filing Analyses(14)
04-03-2026
Texas Instruments Incorporated (TXN) filed Definitive Additional Proxy Materials (DEFA14A) on March 04, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required. No substantive financial or operational details are provided in the available content.
04-03-2026
ImmuCell Corporation reported 2025 product sales of $27.6 million, up 4.3% YoY from $26.5 million, with gross margin expanding to 41.4% from 30% due to higher volumes (380,000 units/month vs. 345,000) and efficiencies, resulting in net operating income of $1.6 million versus a $1.6 million loss in 2024. However, the company posted a net loss of $1.0 million, improved from $2.2 million but driven by one-time charges including a $2.7 million Re-Tain asset write-down, $651,000 colostrum inventory write-down, and $297,000 CEO transition expenses; Q4 saw a net loss of $2.8 million versus a $0.5 million profit. Balance sheet showed stable cash at $3.8 million but a slight decline in stockholders' equity to $27.1 million from $27.5 million.
- Β·EBITDA for 2025 was $2.2 million vs. $1.1 million in 2024.
- Β·Cash from operating activities improved to $2.5 million in 2025 from $0.4 million in 2024.
- Β·Total assets decreased to $42.5 million as of Dec 31, 2025 from $45.1 million as of Dec 31, 2024.
- Β·Conference call scheduled for March 5, 2026 at 9:00 AM ET.
04-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 4, 2026, announcing the issuance of a press release titled 'AITX's RAD Channel Partner Expands Detection to Guard Response Ecosystem,' attached as Exhibit 99.1. The filing discloses a positive development in channel partner expansion integrating detection capabilities into the Guard Response Ecosystem. No financial impacts or quantitative metrics were reported.
04-03-2026
This DEF 14A proxy statement solicits shareholder votes for the election of board members at the virtual annual meeting on April 16, 2026, for Nuveen Virginia Quality Municipal Income Fund (NPV) and 15 other Nuveen funds. For NPV, holders of Common and Preferred Shares vote together to elect four Class II Board Members, while Preferred Share holders vote separately to elect two Board Members. The record date is February 9, 2026, with no financial performance metrics disclosed.
- Β·Annual Meeting: April 16, 2026, at 2:00 p.m. Central Time, virtual only via meetnow.global/M6VY4FD
- Β·Record date: February 9, 2026
- Β·Proxy materials mailed on or about March 6, 2026
- Β·Quorum: Majority of shares for most votes; 33 1/3% of Preferred Shares for their separate election
- Β·Registration for virtual attendance required 3 business days prior if held by intermediary
04-03-2026
Nuveen Quality Municipal Income Fund extended the final mandatory redemption date for its Series 1 Variable Rate Demand Preferred Shares ($236.8M aggregate liquidation preference) and Series 2 Variable Rate Demand Preferred Shares ($267.5M aggregate liquidation preference) from September 11, 2026, to September 11, 2056, effective March 3, 2026. This extension applies to these senior securities, which rank ahead of common shares (NAD) in liquidation and dividends, with weekly dividend rates set by a remarketing agent and liquidity support from a provider. No performance declines or flat metrics were reported in this disclosure.
- Β·Dividends on VRDPs set weekly by remarketing agent, subject to maximum rate that increases during extended unsuccessful remarketing.
- Β·Liquidity feature allows holders to sell to liquidity provider if remarketing fails.
- Β·VRDPs not registered under Securities Act of 1933; disclosure not an offer to sell.
04-03-2026
Texas Instruments Incorporated (TXN) filed its DEF 14A Proxy Statement on March 4, 2026, for the 2026 annual stockholder meeting on April 16, 2026, at 12500 TI Boulevard, Dallas, TX, with a record date of February 23, 2026. Key matters include election of 12 directors (11 independent), advisory approval of executive compensation, ratification of Ernst & Young LLP as independent auditors for 2026, and a stockholder proposal to permit action by written consent. The board emphasizes diverse qualifications including executive leadership, financial acumen, and industry knowledge, with a mandatory retirement age of 75 to balance tenure.
- Β·Quorum requires majority of outstanding shares present in person or by proxy; majority vote of votes cast required for director elections, advisory votes, ratification, and stockholder proposal.
- Β·Advance registration required for in-person attendance by April 15, 2026, with government-issued photo ID; weapons, cameras, and recording devices prohibited.
- Β·Board has 12 nominees, all current directors; substitutes possible if unavailable.
04-03-2026
NCS Multistage Holdings, Inc. filed a Form 8-K on 2026-03-04 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific quantitative financial metrics such as revenue, earnings, margins, or period-over-period comparisons are mentioned in the provided filing details. This appears to be a standard voluntary earnings-related disclosure with no detailed performance data available.
04-03-2026
Costamare Inc. discloses its containership fleet in its 20-F annual report filed on March 04, 2026, consisting of 69 operating vessels with capacities ranging from 1,078 to 14,424 TEU and charter expirations from October 2026 to March 2036, primarily with charterers like Evergreen, MSC, COSCO, and Maersk. Average daily charter rates are provided for select vessels, such as $40,613 for the 14,424 TEU TRITON and $34,881 for the 9,469 TEU SHANGHAI, with TEU-weighted durations up to 6.9 years. Additionally, 10 newbuildings of 3,100 TEU each are under construction, with deliveries scheduled from Q2 2027 to Q4 2028 and employment secured upon delivery.
- Β·Largest vessels: Five 14,424 TEU ships (TRITON, TITAN, TALOS, TAURUS, THESEUS) chartered to Evergreen, expiring 2036.
- Β·Earliest charter expirations: October 2026 (MAERSK PUELO, ARKADIA), with some extendable.
- Β·Many charter details confidential (marked with *) including rates and exact expirations.
- Β·Newbuilding deliveries: Q2-Q4 2027 (4 vessels), Q1-Q4 2028 (6 vessels), with long-term or medium-term employment.
04-03-2026
Broadcom Inc. reported record Q1 FY2026 revenue of $19.3B, up 29% YoY, driven by 52% growth in Semiconductor solutions to $12.5B and 106% YoY increase in AI revenue to $8.4B; however, Infrastructure software grew only 1% YoY to $6.8B. GAAP net income rose 34% YoY to $7.3B but declined 14% QoQ from $8.5B, while Adjusted EBITDA hit $13.1B (+30% YoY, 68% margin). Q2 guidance projects $22.0B revenue (+47% YoY) at 68% Adjusted EBITDA margin, alongside a $0.65/share dividend and new $10B share repurchase program through Dec 31, 2026.
- Β·Cash and equivalents decreased to $14.2B from $16.2B prior quarter.
- Β·Q1 stock-based compensation expense totaled $2,176M.
- Β·Dividend payable March 31, 2026 to shareholders of record March 23, 2026.
04-03-2026
PepGen Inc. reported a slightly narrower net loss of $89.7M for the year ended December 31, 2025, compared to $90.0M in 2024, with operating expenses declining 4.2% YoY to $93.6M driven by a 7.1% drop in R&D expenses, though G&A rose 6.2%. Cash and equivalents grew 22.5% to $60.5M, bolstered by $108M net proceeds from a public offering, resulting in a net cash increase of $11.1M versus a $31.4M decrease prior year; however, interest income fell 43.7% to $4.0M and shares outstanding more than doubled to 68.9M, diluting EPS to $(2.12) from $(2.85). Total assets expanded 15.3% to $173.9M, but accumulated deficit widened to $361.1M.
- Β·Stock-based compensation expense declined to $10.6M from $11.5M YoY.
- Β·Net cash used in investing activities improved to $(15.2M) from $(37.7M), with lower purchases of marketable securities.
- Β·Accumulated deficit increased to $361.1M from $271.5M.
- Β·Employment agreements executed with executives on May 20, 2025 (Kasra Kasrarian, PhD), August 19, 2024 (Paul D. Streck), and December 8, 2025 (Joseph Vittiglio).
04-03-2026
PepGen Inc. reported Q4 and FY 2025 financial results with cash of $148.5M sufficient into 2H 2027, R&D expenses down 27% YoY to $13.9M in Q4 and 7% to $71.0M for the year, and net loss narrowed to $18.3M in Q4 (from $22.2M) and $89.7M for the year (from $90.0M); however, G&A expenses rose 9% YoY to $5.9M in Q4, and an FDA partial clinical hold was placed on the FREEDOM2 trial. Clinical progress includes FREEDOM Phase 1 unblinded data showing dose-proportional splicing correction up to 53.7% at 15 mg/kg, dosing of 4/8 patients in the FREEDOM2 10 mg/kg cohort, and upcoming 5 mg/kg data in Q1 2026. Corporate highlights feature a new USPTO patent for PGN-EDODM1 into 2H 2042 and appointment of Joseph Vittiglio as Chief Business and Legal Officer.
- Β·FDA granted PGN-EDODM1 Orphan Drug and Fast Track Designations; EMA granted Orphan Designation.
- Β·Net loss per share: Q4 2025 $(0.27) vs 2024 $(0.68); FY 2025 $(2.12) vs 2024 $(2.85).
- Β·New USPTO composition of matter patent for PGN-EDODM1 provides exclusivity into 2H 2042, with potential extension.
- Β·FREEDOM2 5 mg/kg cohort data expected Q1 2026; 10 mg/kg cohort data expected 2H 2026; protocol amended for up to 12.5 mg/kg.
- Β·MDA Conference March 8β11, 2026, to present final FREEDOM-DM1 results.
04-03-2026
PepGen Inc. filed an 8-K on March 4, 2026, under Items 7.01 and 9.01, announcing an update to its Corporate Presentation as of March 2026, furnished as Exhibit 99.1. The filing specifies that the information is not deemed 'filed' and is not an admission of materiality.
04-03-2026
On February 26, 2026, Chui Tin Mok, an executive director on the Board of Faraday Future Intelligent Electric Inc., notified the Board of his intent to resign upon confirmation of a successor to focus on business execution in the UAE and Middle East. He will continue serving as an executive officer and Head of FF Middle East. The resignation has no immediate impact as no successor is yet named.
- Β·Trading symbols: FFAI (Class A common stock), FFAIW (redeemable warrants) on Nasdaq Stock Market LLC
- Β·Company confirmed as emerging growth company
- Β·Business address: 18455 S. Figueroa Street, Gardena, CA 90248
- Β·Former name: Property Solutions Acquisition Corp. (changed March 4, 2020)
04-03-2026
A Paradise Acquisition Corp., a SPAC, is pursuing a business combination with Enhanced Ltd, an unproven company with limited operating history and minimal revenue to date, planning to file a Form S-4 registration statement with the SEC. The presentation introduces Enhanced's executive team with pedigrees from organizations like the United States Olympic Committee and Barstool Sports, while highlighting initiatives like the inaugural 2026 Enhanced Games. However, it emphasizes substantial risks including regulatory scrutiny, failure to secure approvals, ethical concerns over performance-enhancement, and dependence on key personnel and financing.
- Β·A Paradise IPO prospectus dated July 29, 2025.
- Β·Form S-4 registration statement to be filed with SEC, including proxy statement/prospectus.
- Β·Contact: The Sunβs Group Center, 29th Floor, 200 Gloucester Road, Wan Chai, Hong Kong; +852 9583 3199.
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 14 filings
πΊπΈ More from United States
View all βMarch 26, 2026
US Pre-Market SEC Filings Roundup β March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals β March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) β March 25, 2026
New Drug Approvals (Original)